Table 1 Treatment-related adverse events during neoadjuvant treatment
Any grade | Grade 3 | |
|---|---|---|
Any TRAE | 20 (100.0%) | 8 (40.0%) |
Lymphocyte count decrease | 18 (90.0%) | 3 (15.0%) |
Platelet count decrease | 14 (70.0%) | 1 (5.0%) |
White blood cell decrease | 13 (65.0%) | 2 (10.0%) |
Aspartate aminotransferase increase | 9 (45.0%) | 2 (10.0%) |
Hypoalbuminemia | 9 (45.0%) | 0 |
Neutrophil count decrease | 8 (40.0%) | 3 (15.0%) |
Anemia | 7 (35.0%) | 0 |
Alanine aminotransferase increase | 5 (25.0%) | 1 (5.0%) |
Blood lactate dehydrogenase increase | 5 (25.0%) | 0 |
Abdominal distension | 5 (25.0%) | 0 |
Fatigue | 5 (25.0%) | 0 |
Nausea | 5 (25.0%) | 0 |
Electrocardiogram T wave abnormal | 5 (25.0%) | 0 |
Blood bilirubin increase | 4 (20.0%) | 0 |
Alkaline phosphatase increase | 4 (20.0%) | 0 |
Hyponatremia | 4 (20.0%) | 0 |
GGT increase | 3 (15.0%) | 0 |
Fibrinogen decrease | 3 (15.0%) | 0 |
Hypokalemia | 2 (10.0%) | 0 |
Hypothyroidism | 2 (10.0%) | 0 |
Activated partial thromboplastin time prolonged | 2 (10.0%) | 0 |
Ascites | 1 (5.0%) | 0 |
Cardiac troponin T increase | 1 (5.0%) | 0 |
INR increase | 1 (5.0%) | 0 |
Thyroid stimulating hormone increase | 1 (5.0%) | 0 |
Abdominal pain | 1 (5.0%) | 0 |
Pneumonitis | 0 | 0 |
